Screening of high-risk families for pancreatic cancer

Pancreatology

Volumn 9, Issue 3, 2009, Pages 215-222

  Greenhalf, W ^a   Grocock, C ^a   Harcus, M ^a   Neoptolemos, J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Endoscopic ultrasound; Familial pancreatic cancer; Hereditary pancreatitis; Molecular screening

Indexed keywords

ASPIRATION BIOPSY; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; FAMILIAL CANCER; FAMILY; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; MEDICAL RESEARCH; MOLECULAR IMAGING; MUTATION; PALLADIN GENE; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TUMOR GENE; UNITED STATES;

EID: 63649153084     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000210262     Document Type: Article

References (57)

1. Shimizu Y, Yasui K, Matsueda K, et al: Small carcinoma of the pancreas is curable:new c omputed tomog raphy finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005;20:1591-1594.
2. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
3. Cress RD, Yin D, Clarke L, et al: Survival among patients with adenocarcinoma of the pancreas:a population-based study (United States). Cancer Causes Control 2006;17:403-409.
4. Satake K, Takeuchi T, Homma T, et al: CA19-9 as a screening and diagnostic tool in symptomatic patients. Pancreas 1994;9:703-706.
5. Kim JE, Lee KT, Lee JK, et al: Clinical usefulness of carbohydrate a ntigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.
6. Rulyak SJ, Brentnall TA:Inherited pancreatic cancer:surveillance and treatment strategies for affected families. Pancreatology 2001;1:477-485.
7. Canto MI, Goggins M, Yeo CJ, et al: Screening for pancreatic neoplasia in high-risk individuals:an EUS-based approach. Clin Gast roenterol Hepatol 2004;2:606-621.
8. Canto MI, Goggins M, Hruban RH, et al: Screening for early pancreatic neoplasia in high-risk individuals:a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-781;quiz 665.
9. Brentnall TA, Bronner MP, Byrd DR, et al: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-255.
10. Greenhalf W, Malats N, Nilsson M, Bartsch D, Neoptolemos J:International Registries of Families at High Risk of Pancreatic Cancer. Pancreatology 2008;8:558-565.
11. Del Chiaro M, Zerbi A, Falconi M, et al: Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 2007;7:459-469.
12. Brand RE, Lerch MM, Rubinstein WS, et al: Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56:14 6 0-14 6 9.
13. Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr, et al: Familial pancreatic cancer. Part 1. Genetic pathology review. Nebr Med J 1989;74:109-112.
14. Aston CE, Banke MG, McNamara PJ, et al: Segregation analysis of pancreatic cancer (abstract). Am J Hum Genet 1997;61:A194.
15. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Nat l Ca ncer Inst 2003;95:214-221.
16. Fay MP, Pfeiffer R, Cronin KA, et al: Age-conditional probabilities of developing cancer. Stat Med 2003;22:18 3 7-18 4 8.
17. Grocock CJ, Vitone LJ, Harcus MJ, et al: Familial pancreatic cancer:a review and latest advances. Adv Med Sci 2007;52:37-49.
18. Howes N, Lerch MM, Greenhalf W, et al: Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroen-terol Hepatol 2004;2:252-2 61.
19. Rebours V, Boutron-Ruault MC, Schnee M, et al: Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis:a national exhaustive series. Am J Gastroenterol 2008;103:111-119..
20. Lowenfels AB, Maisonneuve P, DiMagno EP, et al: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-446.
21. Vitone L, Greenhalf W, Neoptolemos JP: Secondary screening for pancreatic cancer in high-risk groups;in Gress TM, Neoptolemos JP, Lemoine NR, Real FX (eds): Exo-crine Pancreas Cancer:EPC-RC. Hannover, Felsenstein CCCP, 2005, pp 44-61.
22. Freeman ML, DiSario JA, Nelson DB, et al: Risk factors for post-ERCP pancreatitis:a prospective, multicenter study. Gastrointest Endosc 2001;54:425-434.
23. Giardiello FM, Brensinger JD, Tersmette AC, et al: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119 :14 4 7-14 53.
24. Hemminki A, Markie D, Tomlinson I, et al: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-187.
25. Jenne DE, Reimann H, Nezu J, et al: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
26. Grutzmann R, McFaul C, Bartsch DK, et al: No evidence for germline mutations of the LK B1/STK11 gene in familia l pa ncreatic carcinoma. Cancer Let t 2004;214 :63-68.
27. Lynch HT, Brand RE, Hogg D, et al: Pheno-typic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families:the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002;94:84-96.
28. Bartsch DK, Sina-Frey M, Lang S, et al: Cdkn 2a germline mutations in familial pancreatic cancer. Ann Surg 2002;236:730-737.
29. Thompson D, Easton DF: Cancer incidence in brca1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
30. Glasgow RE, Jackson HH, Neumayer L, et al: Pancreatic resection in veterans affairs and selected university medical centers:results of the patient safety in surgery study. J Am Coll Surg 2007;204:1252-1260.
31. Luo J, Adami HO, Reilly M, et al: Interpreting trends of pancreatic cancer incidence and mortality:a nationwide study in Sweden (1960-2003). Cancer Causes Control 2008;19:89- 96.
32. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
33. Jung KW, Kim MH, Lee TY, et al: Clinico-pathological aspects of 542 cases of pancreatic cancer:a special emphasis on small pancreatic cancer. J Korean Med Sci 2007;22(suppl):S79-S85.
34. McFaul C, Greenhalf W, Earl J, et al: Anticipation in familial pancreatic cancer. Gut 2006;55:252-258.
35. Riker A, Libutti SK, Bartlett DL: Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 1997;6:157-169.
36. Ritts RE, Pitt HA:CA19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998;7:93-101.
37. Evans JP, Burke W, Chen R, et al: Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 1995;32:33 0-335.
38. Earl J, Yan L, Vitone LJ, et al: Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1948-1955.
39. Permert J, Adrian TE, Jacobsson P, et al: Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg 1993;165:61-67.
40. Basso D, Greco E, Fogar P, et al: Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta 2006;372:120-128.
41. Goldstein AM, Fraser MC, Struewing JP, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutat ions. N Engl J Med 1995;333:970-974.
42. Kalra MK, Maher MM, Mueller PR, et al: State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 2003;76:857-865.
43. Harewood GC, Wiersema LM, Halling AC, et al: Influence of EUS training and pathology interpretation on accuracy of EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc 2002;55:669-673.
44. Hruban RH, Takaori K, Klimstra DS, et al: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977-987.
45. Barthet M, Portal I, Boujaoude J, et al: Endo-scopic ultrasonographic diagnosis of pancreatic cancer complicating chronic pancreatitis. Endoscopy 1996;28:487-491.
46. Varadarajulu S, Tamhane A, Eloubeidi MA: Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc 2005;62:728-736;quiz 751, 753.
47. Gangi S, Fletcher JG, Nathan MA, et al: Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer:retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 2004;182:897-903.
48. Saisho H, Yamaguchi T: Diagnostic imaging for pancreatic cancer:computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 2004; 28:273-278.
49. Semelka RC, Armao DM, Elias J Jr, et al: Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J Magn Reson Imaging 2007;25:900-909.
50. Diehl SJ, Lehmann KJ, Gaa J, et al: MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate. Invest Radiol 1999;34:589-595.
51. Yan L, McFaul C, Howes N, et al: Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005;128:2124-2130.
52. Cheng CL, Sherman S, Watkins JL, et al: Risk factors for post-ERCP pancreatitis:a prospective multicenter study. Am J Gastroenterol 2006;101:139-147.
53. Williams EJ, Taylor S, Fairclough P, et al: Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut 2007;56:821-829.
54. Carlson C, Greenhalf W, Brentnall TA: Screening of hereditary pancreatic cancer families;in Beger HG, Büchler M, Kozarek R, Lerch M, Neoptolemos J, Warshaw A, Whitcomb D, Shiratori K (eds):The Pancreas:An Integrated Textbook of Basic Science, Medicine and Surgery. Screening of Hereditary Pancreatic Cancer Families, Blackwell, 2008, pp 636-642. *Includes a description of the results from the screening programme of the Washington group.
55. Topazian M, Enders F, Kimmey M, Brand R, Chak A, Clain J, Cunningham J, Eloubeidi M, Gerdes H, Gress F, Jagannath S, Kantsevoy S, LeBlanc JK, Levy M, Lightdale C, Romagnuolo J, Saltzman JR, Savides T, Wiersema M, Woodward T, Petersen G, Canto M: Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointestinal endoscopy 2007;66:62-67.
56. Sugiyama M, Suzuki Y, Abe N, Mori T, Atomi Y: Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 2008;43:181-185.
57. Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, Takakura R, Ishida T, Takano Y, Tanaka S, Takenaka A: Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008;57:1561-1565.